- The utility of ezetimibe therapy in nonalcoholic fatty liver disease
-
Jun BG, Cheon GJ
- KMID: 2441006
- Korean J Intern Med.
- 2019 Mar;34(2):284-285.
- doi: 10.3904/kjim.2019.043
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of ezetimibe and simvastatin combination in Korean hypercholesterolemic patients
-
Park JH
- KMID: 2252428
- Korean J Med.
- 2005 May;68(5):473-475.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
-
Sohn TS
- KMID: 2466512
- Diabetes Metab J.
- 2019 Dec;43(6):909-910.
- doi: 10.4093/dmj.2019.0205
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
-
Lee JB, Kim GS, Cho HN
- KMID: 2368409
- J Stroke.
- 2017 Jan;19(1):109-110.
- doi: 10.5853/jos.2016.00409
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
-
Hwang YC
- KMID: 2466515
- Diabetes Metab J.
- 2019 Dec;43(6):915-916.
- doi: 10.4093/dmj.2019.0213
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Simvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients
-
Choi JW, Suh DW, Lew BL, Sim WY
- KMID: 2395184
- Ann Dermatol.
- 2017 Dec;29(6):755-760.
- doi: 10.5021/ad.2017.29.6.755
BACKGROUND: Simvastatin belongs to the statin family, whose members have immunomodulatory activities. Ezetimibe have synergetic effects when co-administered with simvastatin. In several case reports, alopecia totalis and alopecia universalis were... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects
-
Hwang I, Park SI, Lee S, Lee B, Yu KS, Jeon JY, Kim MG
- KMID: 2420303
- Transl Clin Pharmacol.
- 2018 Mar;26(1):16-24.
- doi: 10.12793/tcp.2018.26.1.16
This study aimed to compare the pharmacokinetics of fixed-dose combination (FDC) tablet of rosuvastatin 20 mg/ezetimibe 10 mg with that of concurrent administration of individual rosuvastatin 20 mg tablet and... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
-
Choi YH, Kim Y, Hyeon CW, Hyun S, Kwon JE, Won H, Shin SY, Lee WS, Lee KJ, Kim SW, Kim TH, Kim CJ
- KMID: 2223883
- Korean Circ J.
- 2014 Jul;44(4):227-232.
- doi: 10.4070/kcj.2014.44.4.227
BACKGROUND AND OBJECTIVES: The inhibition of cholesterol absorption by ezetimibe increases cholesterol synthesis. The effect of inhibition of cholesterol synthesis on cholesterol absorption is controversial. The influence of these interactions... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers
-
Park J, Kim CO, Jin BH, Yang S, Park MS, Hong T
- KMID: 2407003
- Transl Clin Pharmacol.
- 2017 Dec;25(4):202-208.
- doi: 10.12793/tcp.2017.25.4.202
Atorvastatin and ezetimibe are frequently co-administered to treat patients with dyslipidemia for the purpose of low-density lipoprotein cholesterol control. However, pharmacokinetic (PK) drug interaction between atorvastatin and ezetimibe has not... -
- CITED
-
- Close
- SHARE
-
- Close
- The Glucotoxicity Protecting Effect of Ezetimibe in Pancreatic Beta Cells via Inhibition of CD36
-
Yoon JS, Moon JS, Kim YW, Won KC, Lee HW
- KMID: 2363693
- J Korean Med Sci.
- 2016 Apr;31(4):547-552.
- doi: 10.3346/jkms.2016.31.4.547
Inhibition of CD36, a fatty acid transporter, has been reported to prevent glucotoxicity and ameliorate high glucose induced beta cell dysfunction. Ezetimibe is a selective cholesterol absorption inhibitor that blocks... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients
-
Oh MS, Min YJ, Kwon JE, Cho EJ, Kim JE, Lee WS, Lee KJ, Kim SW, Kim TH, Kim CJ, Ryu WS
- KMID: 2297932
- Korean Circ J.
- 2011 May;41(5):253-258.
- doi: 10.4070/kcj.2011.41.5.253
BACKGROUND AND OBJECTIVES: Ezetimibe alone does not decrease C-reactive protein (CRP) levels in hypercholesterolemic patients. However, several reports have suggested that ezetimibe might potentiate the effect of statin not only... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
-
Choi JY, Na JO
- KMID: 2458383
- J Lipid Atheroscler.
- 2019 Sep;8(2):183-191.
- doi: 10.12997/jla.2019.8.2.183
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of ezetimibe on lipid profiles and hemostatic markers in end-stage renal disease
-
Park KS, Yeo YS, Yoo MH, Choi JS, Jang JW, Boo SJ, Yoo DJ, Kim SB
- KMID: 2258370
- Korean J Med.
- 2009 Oct;77(4):461-471.
BACKGROUND/AIMS: Dyslipidemia is one of the major causes of cardiovascular disease in end-stage renal disease (ESRD) patients. Most of them are dyslipidemic despite the use of lipid-lowering agents. Ezetimibe is... -
- CITED
-
- Close
- SHARE
-
- Close
- Lipid-Lowering Therapy Guidelines
-
Lee SH
- KMID: 2462823
- Korean J Med.
- 2019 Oct;94(5):396-402.
- doi: 10.3904/kjm.2019.94.5.396
The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit†is the main idea underlying all guidelines, there are... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination pharmacotherapy in lipid management
-
Lee SH
- KMID: 2195067
- J Korean Med Assoc.
- 2015 Aug;58(8):745-749.
- doi: 10.5124/jkma.2015.58.8.745
Latest guidelines on lipid management recommend statins as the first-line therapy. Because limited evidence is available on cardiovascular outcomes with varying statin-nonstatin combinations, recommendation levels for these regimens have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
-
Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY
- KMID: 2460952
- Diabetes Metab J.
- 2019 Oct;43(5):582-589.
- doi: 10.4093/dmj.2018.0124
BACKGROUND: The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids. Statin and ezetimibe combination therapy have shown additional cardioprotective... -
- CITED
-
- Close
- SHARE
-
- Close
- The safety and efficacy of ezetimibe and simvastatin combination therapy in Korean patients with primary hypercholesterolemia
-
Bae JW, Kim HS, Lee SC, Han KH, Jeon ES
- KMID: 2252431
- Korean J Med.
- 2005 May;68(5):487-497.
BACKGROUND: The prevalence of hypercholesterolemia in Korea is growing. In spite of the wide use of HMG-CoA reductase inhibitors (statins), some patients don't reach optimal cholesterol reduction and suffer hepatotoxicity... -
- CITED
-
- Close
- SHARE
-
- Close
- Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
-
Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH
- KMID: 2441009
- Korean J Intern Med.
- 2019 Mar;34(2):296-304.
- doi: 10.3904/kjim.2017.194
BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Statins on the Epicardial Fat Thickness in Patients with Coronary Artery Stenosis Underwent Percutaneous Coronary Intervention: Comparison of Atorvastatin with Simvastatin/Ezetimibe
-
Park JH, Park YS, Kim YJ, Lee IS, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW
- KMID: 2177312
- J Cardiovasc Ultrasound.
- 2010 Dec;18(4):121-126.
- doi: 10.4250/jcu.2010.18.4.121
BACKGROUND: Epicardial fat is a visceral thoracic fat and known to be related with presence of dyslipidemia and coronary arterial stenosis. We evaluated the effects and differences of statins on... -
- CITED
-
- Close
- SHARE
-
- Close
- Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
-
Kim J, Lee K, Kim J, Lee JM, Kim NY, Lee MS, Ji E
- KMID: 2452862
- Korean J Clin Pharm.
- 2019 Jun;29(2):133-137.
- doi: 10.24304/kjcp.2019.29.2.133
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have... -
- CITED
-
- Close
- SHARE
-
- Close
